

Goals of the Meeting:

This Workshop shall provide a forum for transfusion experts who manufacture the product, scientists who are investigating its therapeutic and cell culture potential to discuss the latest updates on the field, and also with the regulators on how to classify this blood derived product.

Ample time shall be provided for a highly stimulated discussion.

Sponsors:

International Society for Blood Transfusion (ISBT); American Association of Blood Banks (AABB); Maco Pharma Inc.; Cerus Europe BV; Cook Regentec; PL Bioscience GmbH; Trinova Biochem GmbH; Regional Blood Services Swiss Red Cross Graubünden and Zurich.

Target groups:

- Regulators
- Manufacturers of HPL for laboratory or human cell therapy use
- Blood establishments, Transfusion medicine specialists
- Users and developers of ATMPs
- Clinicians (Aesthetic, oral, trauma, plastic and orthopedic surgeons, dermatologists)
- Researchers
- Veterinarians

Start of Meeting: Thursday March 22, 09.00 AM

End of Meeting: Friday March 23, 16.00 PM

Participation fee: € 200 (including Thursday Dinner)

Registration form: Send E-mail to: hplworkshop@zhbsd.ch

Hotel Addresses: Send E-mail to: hplworkshop@zhbsd.ch

Attendants: Limited to 40



International Society
of Blood Transfusion



Human Platelet Lysate – Current Standards and Future Developments

Workshop organized by the Working Party
Cellular Therapies of the ISBT

March 22-23, 2018 Zurich, Switzerland

Venue	Blood Service Swiss Red Cross Zurich, Rütistrasse 19, CH-8952, Zurich-Schlieren, Switzerland
Online Programme	www.isbtweb.org
Organizers	Thierry Burnouf (Taipei, Taiwan) Christian Gabriel (Linz, Austria) Reinhard Henschler (Zurich, Switzerland) Mickey Koh (London, UK) Katharina Schallmoser (Salzburg, Austria)
Conference Paper	planned to appear in Vox Sanguinis
Congress Secretariate	E-mail: hplworkshop@zhbsd.ch

1: Basic Science of Platelets and Their Potential to Regenerate

Chair: Reinhard Henschler

09.00-09.05	Mickey Koh	Welcome and Introduction
09.05-09.45	Paul Harrison	Overview on Platelet Physiology
09.45-10.15	Meinrad Gawaz	Platelets and Thromboinflammation - Consequences for Organ Regeneration

Wrap-up: [Attributes of platelets needed for HPL – basic list of parameters and features of platelets supporting the use of HPL](#)

- 10.30 - 11.00 Coffee Break -

2: HPL: Viral Safety, Pre-Clinical Studies and Release Testing

Chair: Christian Gabriel

11.00-11.30	Karen Bieback	Evaluation of HPL for Expansion of Human MSCs
11.30-12.00	Katharina Schallmoser	What do we have to consider for Release Testing of GMP-grade HPL?
12.00-12.30	Astrid Schwantes	Expectations on virus safety of HPL

Round table: [which parameters are commonly accepted for release testing?](#)

- 13.00 - 14.00 Lunch Break -

3: How do we Standardize Production of HPL?

Chair: Katharina Schallmoser

14.00-14.30	Jo-Anna Reems	Defining a Pathway to Standardize Human Platelet Lysate
14.30-15.00	Steve Harris	(title to be confirmed)

- 15.00 - 15.30 Coffee Break -

15.30-16.00	Bruno Delorme	A standardized human clinical grade PL manufactured from a qualified and validated process of production
-------------	---------------	--

16.00-16.30 Olafur Sigurjonsson Standardizing Intercept-Treated HPL
Round table: [Accepted protocols, minimum criteria for pool size and standardization of HPL](#)

- 19.30 - 22.00 CONFERENCE DINNER -

4: Clinical Use of HPL

Chair: Thierry Burnouf

09.00-09.30	Claudia Cohn	Platelet-Rich-Plasma: Clinical Efficacy and Quality Control
09.30-10.00	J-Jacques Lataillade	HPL for cell therapy applications

- 10.00 - 10.30 Coffee Break -

10.30-11.00	Christian Gabriel	HPL in Regenerative Medicine and other platelet derived products
11.00-11.30	Dirk Strunk	HPL for Bone Regeneration

Round table: [Accepted protocols, clinical evidence and minimum criteria for clinical use of HPL](#)

- 12.00 - 13.00 Lunch Break -

5: How Can HPL be Regulated?

Chairs: Mickey Koh, Johannes Blümel

13.00-13.30	Mo Heidarani	Regulation of HPL in the U.S.
13.30-14.00	Christian Schärer	Regulation of HPL in Europe

Round table: [Critical criteria for regulation of HPL – consensus?](#)

- 14.30 - 15.00 Coffee Break -

6: Perspectives

Chair: Mickey Koh

15.00-15.30	Thierry Burnouf	Potential Evolution in Production Procedures and Therapies using Human Platelet Lysates
-------------	-----------------	---

15.30-16.00 Mickey Koh
Wrap up, final discussion and conclusions

- 16.00 END OF WORKSHOP -

